

Albrecht Stenzinger

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7660439/publications.pdf>

Version: 2024-02-01

304
papers

16,802
citations

20817

60
h-index

24258

110
g-index

319
all docs

319
docs citations

319
times ranked

22591
citing authors

#	ARTICLE	IF	CITATIONS
1	Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. <i>Annals of Oncology</i> , 2019, 30, 44-56.	1.2	1,742
2	Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. <i>Nature Biotechnology</i> , 2013, 31, 539-544.	17.5	920
3	Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. <i>Annals of Oncology</i> , 2020, 31, 1491-1505.	1.2	658
4	The Novel Histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification System of Lung Adenocarcinoma Is a Stage-Independent Predictor of Survival. <i>Journal of Clinical Oncology</i> , 2012, 30, 1438-1446.	1.6	606
5	Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors. <i>Cancer Discovery</i> , 2020, 10, 1808-1825.	9.4	388
6	SARS-CoV-2 infects and replicates in cells of the human endocrine and exocrine pancreas. <i>Nature Metabolism</i> , 2021, 3, 149-165.	11.9	378
7	Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project. , 2020, 8, e000147.		329
8	Sarcoma classification by DNA methylation profiling. <i>Nature Communications</i> , 2021, 12, 498.	12.8	237
9	Accurate and efficient detection of gene fusions from RNA sequencing data. <i>Genome Research</i> , 2021, 31, 448-460.	5.5	215
10	Classification of Cancer at Prostate MRI: Deep Learning versus Clinical PI-RADS Assessment. <i>Radiology</i> , 2019, 293, 607-617.	7.3	214
11	Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer. <i>British Journal of Cancer</i> , 2013, 109, 2665-2674.	6.4	209
12	The landscape of metastatic progression patterns across major human cancers. <i>Oncotarget</i> , 2015, 6, 570-583.	1.8	208
13	BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis. <i>Blood</i> , 2012, 120, e28-e34.	1.4	199
14	Integrative genomic and transcriptomic analysis of leiomyosarcoma. <i>Nature Communications</i> , 2018, 9, 144.	12.8	197
15	<i>NRG1</i> Fusions in <i>KRAS</i> Wild-Type Pancreatic Cancer. <i>Cancer Discovery</i> , 2018, 8, 1087-1095.	9.4	189
16	CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma. <i>Nature Medicine</i> , 2016, 22, 278-287.	30.7	184
17	Increased microtubule assembly rates influence chromosomal instability in colorectal cancer cells. <i>Nature Cell Biology</i> , 2014, 16, 779-791.	10.3	174
18	Tumor mutational burden standardization initiatives: Recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 578-588.	2.8	173

#	ARTICLE	IF	CITATIONS
19	A field guide for cancer diagnostics using cell-free DNA: From principles to practice and clinical applications. <i>Genes Chromosomes and Cancer</i> , 2018, 57, 123-139.	2.8	155
20	Implementing tumor mutational burden (TMB) analysis in routine diagnostics—a primer for molecular pathologists and clinicians. <i>Translational Lung Cancer Research</i> , 2018, 7, 703-715.	2.8	152
21	Precision oncology based on omics data: The NCT Heidelberg experience. <i>International Journal of Cancer</i> , 2017, 141, 877-886.	5.1	133
22	Automated sample preparation with <i>SP3</i> for low-input clinical proteomics. <i>Molecular Systems Biology</i> , 2020, 16, e9111.	7.2	133
23	Colorectal mixed adenoneuroendocrine carcinomas and neuroendocrine carcinomas are genetically closely related to colorectal adenocarcinomas. <i>Modern Pathology</i> , 2017, 30, 610-619.	5.5	131
24	Size matters: Dissecting key parameters for panel-based tumor mutational burden analysis. <i>International Journal of Cancer</i> , 2019, 144, 848-858.	5.1	131
25	Three molecular pathways model colorectal carcinogenesis in <i>Lynch</i> syndrome. <i>International Journal of Cancer</i> , 2018, 143, 139-150.	5.1	129
26	Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers. <i>Cancer Discovery</i> , 2021, 11, 2780-2795.	9.4	125
27	Optimizing panel-based tumor mutational burden (TMB) measurement. <i>Annals of Oncology</i> , 2019, 30, 1496-1506.	1.2	123
28	Tumour cell proliferation (Ki-67) in non-small cell lung cancer: a critical reappraisal of its prognostic role. <i>British Journal of Cancer</i> , 2014, 111, 1222-1229.	6.4	114
29	The presence of circulating tumor cells (CTCs) correlates with lymph node metastasis in nonresectable squamous cell carcinoma of the head and neck region (SCCHN). <i>Annals of Oncology</i> , 2011, 22, 1878-1885.	1.2	112
30	Molecular Diagnostic Profiling of Lung Cancer Specimens with a Semiconductor-Based Massive Parallel Sequencing Approach. <i>Journal of Molecular Diagnostics</i> , 2013, 15, 765-775.	2.8	107
31	Correlation of radio- and histomorphological pattern of pulmonary adenocarcinoma. <i>European Respiratory Journal</i> , 2013, 41, 943-951.	6.7	105
32	Interobserver variability in the application of the novel IASLC/ATS/ERS classification for pulmonary adenocarcinomas. <i>European Respiratory Journal</i> , 2012, 40, 1221-1227.	6.7	97
33	EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype. <i>European Respiratory Journal</i> , 2014, 43, 872-883.	6.7	97
34	Global alterations of DNA methylation in cholangiocarcinoma target the Wnt signaling pathway. <i>Hepatology</i> , 2014, 59, 544-554.	7.3	97
35	BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma. <i>Modern Pathology</i> , 2014, 27, 1028-1034.	5.5	96
36	<i>ROS1</i> expression and translocations in non-small cell lung cancer: clinicopathological analysis of 1478 cases. <i>Histopathology</i> , 2014, 65, 187-194.	2.9	96

#	ARTICLE	IF	CITATIONS
37	Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: <i>in silico</i> and real-life analysis of three larger gene panels. International Journal of Cancer, 2019, 144, 2303-2312.	5.1	95
38	KRAS Genotyping of Paraffin-Embedded Colorectal Cancer Tissue in Routine Diagnostics. Journal of Molecular Diagnostics, 2010, 12, 35-42.	2.8	94
39	<i>EML4-ALK</i> fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in <i>ALK</i> non-small cell lung cancer. International Journal of Cancer, 2018, 142, 2589-2598.	5.1	93
40	Classical pathology and mutational load of breast cancer – integration of two worlds. Journal of Pathology: Clinical Research, 2015, 1, 225-238.	3.0	91
41	mTOR expression and activity patterns in gastroenteropancreatic neuroendocrine tumours. Endocrine-Related Cancer, 2011, 18, 181-192.	3.1	90
42	Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project. Annals of Oncology, 2021, 32, 1626-1636.	1.2	86
43	Expression of Amphiregulin and EGFRvIII Affect Outcome of Patients with Squamous Cell Carcinoma of the Head and Neck Receiving Cetuximab+Docetaxel Treatment. Clinical Cancer Research, 2011, 17, 5197-5204.	7.0	85
44	Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases. International Journal of Cancer, 2019, 145, 649-661.	5.1	85
45	Prognostic Impact and Clinicopathological Correlations of the Cribriform Pattern in Pulmonary Adenocarcinoma. Journal of Thoracic Oncology, 2015, 10, 638-644.	1.1	83
46	Co-expression of MET and CD47 is a novel prognosticator for survival of luminal-type breast cancer patients. Oncotarget, 2014, 5, 8147-8160.	1.8	83
47	Targeted ultra-deep sequencing reveals recurrent and mutually exclusive mutations of cancer genes in blastic plasmacytoid dendritic cell neoplasm. Oncotarget, 2014, 5, 6404-6413.	1.8	82
48	Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response. Clinical Cancer Research, 2018, 24, 351-359.	7.0	81
49	Harmonization and Standardization of Panel-Based Tumor Mutational Burden Measurement: Real-World Results and Recommendations of the Quality in Pathology Study. Journal of Thoracic Oncology, 2020, 15, 1177-1189.	1.1	81
50	Pan-cancer analysis of copy number changes in programmed death-ligand 1 (PD-L1, CD274) – associations with gene expression, mutational load, and survival. Genes Chromosomes and Cancer, 2016, 55, 626-639.	2.8	80
51	Postoperative Complications Deteriorate Long-Term Outcome in Pancreatic Cancer Patients. Annals of Surgical Oncology, 2012, 19, 856-863.	1.5	78
52	Potential clinical implications of <i>BRAF</i> mutations in histiocytic proliferations. Oncotarget, 2014, 5, 4060-4070.	1.8	78
53	Variant classification in precision oncology. International Journal of Cancer, 2019, 145, 2996-3010.	5.1	76
54	Contribution of human papilloma virus to the incidence of squamous cell carcinoma of the head and neck in a European population with high smoking prevalence. European Journal of Cancer, 2015, 51, 514-521.	2.8	75

#	ARTICLE	IF	CITATIONS
55	The landscape of chromothripsis across adult cancer types. <i>Nature Communications</i> , 2020, 11, 2320.	12.8	75
56	Reliable Entity Subtyping in Non-small Cell Lung Cancer by Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry on Formalin-fixed Paraffin-embedded Tissue Specimens. <i>Molecular and Cellular Proteomics</i> , 2016, 15, 3081-3089.	3.8	72
57	Morphological and molecular breast cancer profiling through explainable machine learning. <i>Nature Machine Intelligence</i> , 2021, 3, 355-366.	16.0	72
58	Survival of Patients with Oral Cavity Cancer in Germany. <i>PLoS ONE</i> , 2013, 8, e53415.	2.5	69
59	Spatial and Temporal Heterogeneity of Panel-Based Tumor Mutational Burden in Pulmonary Adenocarcinoma: Separating Biology From Technical Artifacts. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1935-1947.	1.1	69
60	Homologous Recombination Deficiency: Concepts, Definitions, and Assays. <i>Oncologist</i> , 2022, 27, 167-174.	3.7	69
61	Identification of a highly lethal V3 ⁺ TP53 ⁺ subset in ALK ⁺ lung adenocarcinoma. <i>International Journal of Cancer</i> , 2019, 144, 190-199.	5.1	67
62	High-throughput diagnostic profiling of clinically actionable gene fusions in lung cancer. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 30-44.	2.8	65
63	Defective homologous recombination DNA repair as therapeutic target in advanced chordoma. <i>Nature Communications</i> , 2019, 10, 1635.	12.8	64
64	High SIRT1 expression is a negative prognosticator in pancreatic ductal adenocarcinoma. <i>BMC Cancer</i> , 2013, 13, 450.	2.6	63
65	Integrative Analysis Defines Distinct Prognostic Subgroups of Intrahepatic Cholangiocarcinoma. <i>Hepatology</i> , 2019, 69, 2091-2106.	7.3	63
66	Deep Learning for the Classification of Small-Cell and Non-Small-Cell Lung Cancer. <i>Cancers</i> , 2020, 12, 1604.	3.7	63
67	Patients Resistant Against PSMA-Targeting α -Radiation Therapy Often Harbor Mutations in DNA Damage-Repair-Associated Genes. <i>Journal of Nuclear Medicine</i> , 2020, 61, 683-688.	5.0	61
68	Phenotyping of pulmonary carcinoids and a Ki-67-based grading approach. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2012, 460, 299-308.	2.8	60
69	Loss of SOX2 expression induces cell motility via vimentin up-regulation and is an unfavorable risk factor for survival of head and neck squamous cell carcinoma. <i>Molecular Oncology</i> , 2015, 9, 1704-1719.	4.6	60
70	Integrated analysis of the immunological and genetic status in and across cancer types: impact of mutational signatures beyond tumor mutational burden. <i>Oncolmmunology</i> , 2018, 7, e1526613.	4.6	60
71	Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP). <i>Annals of Oncology</i> , 2019, 30, 161-165.	1.2	60
72	Associations of Pathogenic Variants in MLH1, MSH2, and MSH6 With Risk of Colorectal Adenomas and Tumors and With Somatic Mutations in Patients With Lynch Syndrome. <i>Gastroenterology</i> , 2020, 158, 1326-1333.	1.3	60

#	ARTICLE	IF	CITATIONS
73	Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences. <i>Oncotarget</i> , 2014, 5, 9952-9965.	1.8	58
74	Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with <i>PDL1</i> amplification. <i>Journal of Physical Education and Sports Management</i> , 2016, 2, a001180.	1.2	57
75	Marker chromosomes can arise from chromothripsis and predict adverse prognosis in acute myeloid leukemia. <i>Blood</i> , 2017, 129, 1333-1342.	1.4	57
76	Mutations in <i>POLE</i> and survival of colorectal cancer patients – link to disease stage and treatment. <i>Cancer Medicine</i> , 2014, 3, 1527-1538.	2.8	56
77	Training increases concordance in classifying pulmonary adenocarcinomas according to the novel IASLC/ATS/ERS classification. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2012, 461, 185-193.	2.8	55
78	Distribution of <i>MED12</i> mutations in fibroadenomas and phyllodes tumors of the breast – implications for tumor biology and pathological diagnosis. <i>Genes Chromosomes and Cancer</i> , 2015, 54, 444-452.	2.8	55
79	Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): Joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC). <i>Genetics in Medicine</i> , 2022, 24, 986-998.	2.4	55
80	Major histocompatibility complex class I expression impacts on patient survival and type and density of immune cells in biliary tract cancer. <i>British Journal of Cancer</i> , 2015, 113, 1343-1349.	6.4	54
81	Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315). <i>Lung Cancer</i> , 2021, 152, 174-184.	2.0	53
82	Who Is at Risk for Diagnostic Discrepancies? Comparison of Pre- and Postmortal Diagnoses in 1800 Patients of 3 Medical Decades in East and West Berlin. <i>PLoS ONE</i> , 2012, 7, e37460.	2.5	53
83	Testing <i>NTRK</i> testing: Wet-lab and in silico comparison of RNA-based targeted sequencing assays. <i>Genes Chromosomes and Cancer</i> , 2020, 59, 178-188.	2.8	52
84	MIR-200b and miR-155 as predictive biomarkers for the efficacy of chemoradiation in locally advanced head and neck squamous cell carcinoma. <i>European Journal of Cancer</i> , 2017, 77, 3-12.	2.8	51
85	Recurrent YAP1 and MAML2 Gene Rearrangements in Retiform and Composite Hemangioendothelioma. <i>American Journal of Surgical Pathology</i> , 2020, 44, 1677-1684.	3.7	51
86	PD-L1 (CD274) copy number gain, expression, and immune cell infiltration as candidate predictors for response to immune checkpoint inhibitors in soft-tissue sarcoma. <i>Oncolmmunology</i> , 2017, 6, e1279777.	4.6	50
87	Role of <i>TP53</i> mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy. <i>Oncotarget</i> , 2016, 7, 67686-67698.	1.8	50
88	EWSR1/FUS – CREB fusions define a distinctive malignant epithelioid neoplasm with predilection for mesothelial-lined cavities. <i>Modern Pathology</i> , 2020, 33, 2233-2243.	5.5	49
89	The combinatorial complexity of cancer precision medicine. <i>Oncoscience</i> , 2014, 1, 504-509.	2.2	48
90	Molecular driver alterations and their clinical relevance in cancer of unknown primary site. <i>Oncotarget</i> , 2016, 7, 44322-44329.	1.8	47

#	ARTICLE	IF	CITATIONS
91	Downregulation of the microRNA processing enzyme Dicer is a prognostic factor in human colorectal cancer. <i>Histopathology</i> , 2012, 61, 552-561.	2.9	44
92	Appendiceal goblet cell carcinoids and adenocarcinomas ex-goblet cell carcinoid are genetically distinct from primary colorectal-type adenocarcinoma of the appendix. <i>Modern Pathology</i> , 2018, 31, 829-839.	5.5	44
93	Copy number changes of clinically actionable genes in melanoma, non-small cell lung cancer and colorectal cancer—A survey across 822 routine diagnostic cases. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 821-833.	2.8	43
94	KRAS G12C-mutated advanced non-small cell lung cancer: A real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315). <i>Lung Cancer</i> , 2021, 154, 51-61.	2.0	43
95	Genomic Characterization of Cholangiocarcinoma in Primary Sclerosing Cholangitis Reveals Therapeutic Opportunities. <i>Hepatology</i> , 2020, 72, 1253-1266.	7.3	42
96	Evaluation of a Hybrid Capture–Based Pan-Cancer Panel for Analysis of Treatment Stratifying Oncogenic Aberrations and Processes. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 757-769.	2.8	42
97	Artificial intelligence and pathology: From principles to practice and future applications in histomorphology and molecular profiling. <i>Seminars in Cancer Biology</i> , 2022, 84, 129-143.	9.6	41
98	A gene expression signature associated with B cells predicts benefit from immune checkpoint blockade in lung adenocarcinoma. <i>Onc Immunology</i> , 2021, 10, 1860586.	4.6	40
99	Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for the Prediction of Extraprostatic Disease—A Risk Model for Patient-tailored Risk Stratification When Planning Radical Prostatectomy. <i>European Urology Focus</i> , 2020, 6, 1205-1212.	3.1	39
100	Targeted next-generation sequencing identifies molecular subgroups in squamous cell carcinoma of the head and neck with distinct outcome after concurrent chemoradiation. <i>Annals of Oncology</i> , 2016, 27, 2262-2268.	1.2	38
101	The BRCA2 mutation status shapes the immune phenotype of prostate cancer. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1621-1633.	4.2	38
102	Label-Free Enrichment and Molecular Characterization of Viable Circulating Tumor Cells from Diagnostic Leukapheresis Products. <i>Clinical Chemistry</i> , 2019, 65, 549-558.	3.2	37
103	Cancer beyond organ and tissue specificity: Next-generation sequencing gene mutation data reveal complex genetic similarities across major cancers. <i>International Journal of Cancer</i> , 2014, 135, 2362-2369.	5.1	36
104	KRAS Mutations in Codon 12 or 13 Are Associated With Worse Prognosis in Pancreatic Ductal Adenocarcinoma. <i>Pancreas</i> , 2014, 43, 578-583.	1.1	36
105	Allelic Ratio of <i>KRAS</i> Mutations in Pancreatic Cancer. <i>Oncologist</i> , 2015, 20, e8-e9.	3.7	36
106	ALK-FISH borderline cases in non-small cell lung cancer: Implications for diagnostics and clinical decision making. <i>Lung Cancer</i> , 2015, 90, 465-471.	2.0	36
107	A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in patients with metastatic, inoperable pancreatic cancer: ParvOryx02 protocol. <i>BMC Cancer</i> , 2017, 17, 576.	2.6	36
108	Detection of TP53 Mutations in Tissue or Liquid Rebiopsies at Progression Identifies ALK+ Lung Cancer Patients with Poor Survival. <i>Cancers</i> , 2019, 11, 124.	3.7	36

#	ARTICLE	IF	CITATIONS
109	Hidden Variables in Deep Learning Digital Pathology and Their Potential to Cause Batch Effects: Prediction Model Study. <i>Journal of Medical Internet Research</i> , 2021, 23, e23436.	4.3	36
110	Distinctive Spatiotemporal Stability of Somatic Mutations in Metastasized Microsatellite-stable Colorectal Cancer. <i>American Journal of Surgical Pathology</i> , 2015, 39, 1140-1147.	3.7	35
111	Establishment of a patient-derived orthotopic osteosarcoma mouse model. <i>Journal of Translational Medicine</i> , 2015, 13, 136.	4.4	35
112	Mutation patterns in genes encoding interferon signaling and antigen presentation: A pan-cancer survey with implications for the use of immune checkpoint inhibitors. <i>Genes Chromosomes and Cancer</i> , 2017, 56, 651-659.	2.8	35
113	Tumor Mutational Burden as a Pan-cancer Biomarker for Immunotherapy: The Limits and Potential for Convergence. <i>Cancer Cell</i> , 2020, 38, 624-625.	16.8	35
114	Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer. <i>ESMO Open</i> , 2021, 6, 100254.	4.5	35
115	Defining molecular risk in ALK+ NSCLC. <i>Oncotarget</i> , 2019, 10, 3093-3103.	1.8	35
116	Genotyping of colorectal cancer for cancer precision medicine: Results from the IPH Center for Molecular Pathology. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 505-521.	2.8	34
117	The Value of Prostate-specific Antigen Density for Prostate Imaging-Reporting and Data System 3 Lesions on Multiparametric Magnetic Resonance Imaging: A Strategy to Avoid Unnecessary Prostate Biopsies. <i>European Urology Focus</i> , 2021, 7, 325-331.	3.1	34
118	Cadherin-6 is a putative tumor suppressor and target of epigenetically dysregulated miR-429 in cholangiocarcinoma. <i>Epigenetics</i> , 2016, 11, 780-790.	2.7	33
119	Therapeutic and Prognostic Implications of Immune-Related Adverse Events in Advanced Non-Small-Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 703893.	2.8	33
120	Simultaneous whole-body ¹⁸ F-PSMA-1007-PET/MRI with integrated high-resolution multiparametric imaging of the prostatic fossa for comprehensive oncological staging of patients with prostate cancer: a pilot study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 340-347.	6.4	32
121	RNA-Based Detection of Gene Fusions in Formalin-Fixed and Paraffin-Embedded Solid Cancer Samples. <i>Cancers</i> , 2019, 11, 1309.	3.7	32
122	Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial. <i>Clinical Cancer Research</i> , 2019, 25, 3986-3995.	7.0	32
123	Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA. <i>EBioMedicine</i> , 2020, 62, 103103.	6.1	32
124	Endometrial stromal sarcomas with <i>BCOR</i> rearrangement harbor <i>MDM2</i> amplifications. <i>Journal of Pathology: Clinical Research</i> , 2020, 6, 178-184.	3.0	32
125	Efficacy of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in NSCLC Harboring ERBB2 Mutations. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1952-1958.	1.1	32
126	Fusion-positive non-small cell lung carcinoma: Biological principles, clinical practice, and diagnostic implications. <i>Genes Chromosomes and Cancer</i> , 2022, 61, 244-260.	2.8	32

#	ARTICLE	IF	CITATIONS
127	High nuclear poly(ADP-ribose) polymerase expression is prognostic of improved survival in pancreatic cancer. <i>Histopathology</i> , 2012, 61, 409-416.	2.9	31
128	High extracellular matrix metalloproteinase inducer/CD147 expression is strongly and independently associated with poor prognosis in colorectal cancer. <i>Human Pathology</i> , 2012, 43, 1471-1481.	2.0	30
129	Mutant KIT as imatinib-sensitive target in metastatic sinonasal carcinoma. <i>Annals of Oncology</i> , 2017, 28, 142-148.	1.2	30
130	Mutations in genes encoding <i>PI3K-AKT</i> and <i>MAPK</i> signaling define anogenital papillary hidradenoma. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 113-119.	2.8	29
131	EGFR T790M mutation testing of non-small cell lung cancer tissue and blood samples artificially spiked with circulating cell-free tumor DNA: results of a round robin trial. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 509-520.	2.8	29
132	<i>RSPO2</i> gene rearrangement: a powerful driver of β -catenin activation in liver tumours. <i>Gut</i> , 2019, 68, 1287-1296.	12.1	29
133	Genetic heterogeneity in synchronous colorectal cancers impacts genotyping approaches and therapeutic strategies. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 268-277.	2.8	28
134	Quantifying potential confounders of panel-based tumor mutational burden (TMB) measurement. <i>Lung Cancer</i> , 2020, 142, 114-119.	2.0	28
135	Standardized Magnetic Resonance Imaging Reporting Using the Prostate Cancer Radiological Estimation of Change in Sequential Evaluation Criteria and Magnetic Resonance Imaging/Transrectal Ultrasound Fusion with Transperineal Saturation Biopsy to Select Men on Active Surveillance. <i>European Urology Focus</i> , 2021, 7, 102-110.	3.1	28
136	p53 partial loss-of-function mutations sensitize to chemotherapy. <i>Oncogene</i> , 2022, 41, 1011-1023.	5.9	28
137	Tubular, lactating, and ductal adenomas are devoid of MED12 Exon2 mutations, and ductal adenomas show recurrent mutations in GNAS and the PI3K-AKT pathway. <i>Genes Chromosomes and Cancer</i> , 2017, 56, 11-17.	2.8	27
138	Targeted molecular profiling reveals genetic heterogeneity of poromas and porocarcinomas. <i>Pathology</i> , 2018, 50, 327-332.	0.6	27
139	In-house Implementation of Tumor Mutational Burden Testing to Predict Durable Clinical Benefit in Non-small Cell Lung Cancer and Melanoma Patients. <i>Cancers</i> , 2019, 11, 1271.	3.7	27
140	<i>NTRK</i> testing: First results of the <i>QuiP-EQA</i> scheme and a comprehensive map of <i>NTRK</i> fusion variants and their diagnostic coverage by targeted <i>RNA</i> -based <i>NGS</i> assays. <i>Genes Chromosomes and Cancer</i> , 2020, 59, 445-453.	2.8	27
141	Novel GATA6-FOXO1 fusions in a subset of epithelioid hemangioma. <i>Modern Pathology</i> , 2021, 34, 934-941.	5.5	27
142	Fully Automatic Deep Learning in Bi-institutional Prostate Magnetic Resonance Imaging. <i>Investigative Radiology</i> , 2021, 56, 799-808.	6.2	27
143	The Different Immune Profiles of Normal Colonic Mucosa in Cancer-Free Lynch Syndrome Carriers and Lynch Syndrome Colorectal Cancer Patients. <i>Gastroenterology</i> , 2022, 162, 907-919.e10.	1.3	27
144	The novel protein PTPIP51 exhibits tissue- and cell-specific expression. <i>Histochemistry and Cell Biology</i> , 2005, 123, 19-28.	1.7	26

#	ARTICLE	IF	CITATIONS
145	EML4-ALK V3, treatment resistance, and survival: refining the diagnosis of ALK+ NSCLC. Journal of Thoracic Disease, 2018, 10, S1989-S1991.	1.4	26
146	Risk stratification of EGFR+ lung cancer diagnosed with panel-based next-generation sequencing. Lung Cancer, 2020, 148, 105-112.	2.0	26
147	Chapter 6 Cell and Molecular Biology of the Novel Protein Tyrosineâ€Phosphataseâ€Interacting Protein 51. International Review of Cell and Molecular Biology, 2009, 275, 183-246.	3.2	25
148	Fibroblast Growth Factor Receptor 1 as a Putative Therapy Target in Colorectal Cancer. Digestion, 2013, 88, 172-181.	2.3	25
149	Prevalence of somatic mitochondrial mutations and spatial distribution of mitochondria in non-small cell lung cancer. British Journal of Cancer, 2017, 117, 220-226.	6.4	25
150	NGS-based BRCA1/2 mutation testing of high-grade serous ovarian cancer tissue: results and conclusions of the first international round robin trial. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 468, 697-705.	2.8	24
151	Comparative genetic profiling aids diagnosis and clinical decision making in challenging cases of CUP syndrome. International Journal of Cancer, 2019, 145, 2963-2973.	5.1	24
152	Histopathological to multiparametric MRI spatial mapping of extended systematic sextant and MR/TRUS-fusion-targeted biopsy of the prostate. European Radiology, 2019, 29, 1820-1830.	4.5	24
153	Simulated clinical deployment of fully automatic deep learning for clinical prostate MRI assessment. European Radiology, 2021, 31, 302-313.	4.5	24
154	Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancer. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592199650.	3.2	24
155	Combined Immunohistochemistry after Mass Spectrometry Imaging for Superior Spatial Information. Proteomics - Clinical Applications, 2019, 13, e1800035.	1.6	23
156	Conceptual framework for precision cancer medicine in Germany: Consensus statement of the Deutsche Krebshilfe working group â€Molecular Diagnostics and Therapyâ€™. European Journal of Cancer, 2020, 135, 1-7.	2.8	23
157	Efficacy of docetaxel plus ramucirumab as palliative second-line therapy following first-line chemotherapy plus immune-checkpoint-inhibitor combination treatment in patients with non-small cell lung cancer (NSCLC) UICC stage IV. Translational Lung Cancer Research, 2021, 10, 3093-3105.	2.8	23
158	Targetable ERBB2 mutations identified in neurofibroma/schwannoma hybrid nerve sheath tumors. Journal of Clinical Investigation, 2020, 130, 2488-2495.	8.2	23
159	loncopy: a novel method for calling copy number alterations in amplicon sequencing data including significance assessment. Oncotarget, 2016, 7, 13236-13247.	1.8	23
160	Pan-cancer analysis of genomic scar patterns caused by homologous repair deficiency (HRD). Npj Precision Oncology, 2022, 6, .	5.4	23
161	The putative oncogene CEP72 inhibits the mitotic function of BRCA1 and induces chromosomal instability. Oncogene, 2016, 35, 2398-2406.	5.9	22
162	KIT-Dependent and KIT-Independent Genomic Heterogeneity of Resistance in Gastrointestinal Stromal Tumors â€” TORC1/2 Inhibition as Salvage Strategy. Molecular Cancer Therapeutics, 2019, 18, 1985-1996.	4.1	22

#	ARTICLE	IF	CITATIONS
163	Global DNA methylation reflects spatial heterogeneity and molecular evolution of lung adenocarcinomas. International Journal of Cancer, 2019, 144, 1061-1072.	5.1	22
164	Trailblazing precision medicine in Europe: A joint view by Genomic Medicine Sweden and the Centers for Personalized Medicine, ZPM, in Germany. Seminars in Cancer Biology, 2022, 84, 242-254.	9.6	22
165	Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma. Cancer Immunology, Immunotherapy, 2022, 71, 251-265.	4.2	22
166	Precision oncology: a clinical and patient perspective. Future Oncology, 2021, 17, 3995-4009.	2.4	22
167	GOT1/AST1 expression status as a prognostic biomarker in pancreatic ductal adenocarcinoma. Oncotarget, 2015, 6, 4516-4526.	1.8	22
168	Epidermal Growth Factor-, Transforming Growth Factor- β 2-, Retinoic Acid- and 1,25-Dihydroxyvitamin D ₃ -Regulated Expression of the Novel Protein PTPIP51 in Keratinocytes. Cells Tissues Organs, 2006, 184, 76-87.	2.3	21
169	Mutational profiles of Brenner tumors show distinctive features uncoupling urothelial carcinomas and ovarian carcinoma with transitional cell histology. Genes Chromosomes and Cancer, 2017, 56, 758-766.	2.8	21
170	Spatial distribution of EGFR and KRAS mutation frequencies correlates with histological growth patterns of lung adenocarcinomas. International Journal of Cancer, 2017, 141, 1841-1848.	5.1	21
171	Targeted next-generation sequencing enables reliable detection of HER2 (ERBB2) status in breast cancer and provides ancillary information of clinical relevance. Genes Chromosomes and Cancer, 2017, 56, 255-265.	2.8	21
172	Genetic profiling of melanoma in routine diagnostics: assay performance and molecular characteristics in a consecutive series of 274 cases. Pathology, 2018, 50, 703-710.	0.6	21
173	Role of Synaptophysin, Chromogranin and CD56 in adenocarcinoma and squamous cell carcinoma of the lung lacking morphological features of neuroendocrine differentiation: a retrospective large-scale study on 1170 tissue samples. BMC Cancer, 2021, 21, 486.	2.6	21
174	Early identification of disease progression in ALK-rearranged lung cancer using circulating tumor DNA analysis. Npj Precision Oncology, 2021, 5, 100.	5.4	21
175	Validating Comprehensive Next-Generation Sequencing Results for Precision Oncology: The NCT/DTK Molecularly Aided Stratification for Tumor Eradication Research Experience. JCO Precision Oncology, 2018, 2, 1-13.	3.0	20
176	CATCH: A Prospective Precision Oncology Trial in Metastatic Breast Cancer. JCO Precision Oncology, 2021, 5, 676-686.	3.0	20
177	Individualized medicine and demographic change as determining workload factors in pathology: quo vadis?. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 468, 101-108.	2.8	19
178	Nivolumab maintenance after salvage autologous stem cell transplantation results in long-term remission in multiple relapsed primary CNS lymphoma. European Journal of Haematology, 2018, 101, 115-118.	2.2	19
179	Targeted deep sequencing of effusion cytology samples is feasible, informs spatiotemporal tumor evolution, and has clinical and diagnostic utility. Genes Chromosomes and Cancer, 2018, 57, 70-79.	2.8	19
180	Digital PCR After MALDI-Mass Spectrometry Imaging to Combine Proteomic Mapping and Identification of Activating Mutations in Pulmonary Adenocarcinoma. Proteomics - Clinical Applications, 2019, 13, e1800034.	1.6	19

#	ARTICLE	IF	CITATIONS
181	Identification and characterization of a BRAF fusion oncoprotein with retained autoinhibitory domains. <i>Oncogene</i> , 2020, 39, 814-832.	5.9	19
182	Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer. <i>Journal of Pathology: Clinical Research</i> , 2021, 7, 311-325.	3.0	19
183	Oncogenic driver mutations, treatment, and EGFR-TKI resistance in a Caucasian population with non-small cell lung cancer: survival in clinical practice. <i>Oncotarget</i> , 2017, 8, 77897-77914.	1.8	19
184	Expression profile of PTP51 in mouse brain. <i>Journal of Comparative Neurology</i> , 2009, 517, 892-905.	1.6	18
185	Quantitative Analysis of Diagnostic Guidelines for HER2-Status Assessment. <i>Journal of Molecular Diagnostics</i> , 2012, 14, 199-205.	2.8	18
186	Comparison of Prostate MRI Lesion Segmentation Agreement Between Multiple Radiologists and a Fully Automatic Deep Learning System. <i>RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren</i> , 2021, 193, 559-573.	1.3	18
187	Intimal sarcomas and undifferentiated cardiac sarcomas carry mutually exclusive MDM2, MDM4, and CDK6 amplifications and share a common DNA methylation signature. <i>Modern Pathology</i> , 2021, 34, 2122-2129.	5.5	17
188	The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma. <i>ESMO Open</i> , 2021, 6, 100253.	4.5	17
189	The novel protein PTP51 is expressed in human keratinocyte carcinomas and their surrounding stroma. <i>Journal of Cellular and Molecular Medicine</i> , 2008, 12, 2083-2095.	3.6	16
190	Follicle-stimulating hormone receptor expression in soft tissue sarcomas. <i>Histopathology</i> , 2013, 63, 29-35.	2.9	16
191	Clinical and molecular characteristics of HNSCC patients with brain metastases: a retrospective study. <i>European Archives of Oto-Rhino-Laryngology</i> , 2014, 271, 1715-1722.	1.6	16
192	Targeting irradiation-induced mitogen-activated protein kinase activation in vitro and in an ex vivo model for human head and neck cancer. <i>Head and Neck</i> , 2016, 38, E2049-61.	2.0	16
193	Subclonal evolution of pulmonary adenocarcinomas delineated by spatially distributed somatic mitochondrial mutations. <i>Lung Cancer</i> , 2018, 126, 80-88.	2.0	16
194	Homologous recombination repair deficiency (HRD): From biology to clinical exploitation. <i>Genes Chromosomes and Cancer</i> , 2021, 60, 299-302.	2.8	16
195	Recurrent YAP1-TFE3 Gene Fusions in Clear Cell Stromal Tumor of the Lung. <i>American Journal of Surgical Pathology</i> , 2021, 45, 1541-1549.	3.7	16
196	Earlier extracranial progression and shorter survival in ALK- rearranged lung cancer with positive liquid rebiopsies. <i>Translational Lung Cancer Research</i> , 2021, 10, 2118-2131.	2.8	16
197	GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types. <i>Acta Neuropathologica</i> , 2021, 142, 1065-1069.	7.7	16
198	Safety and Preliminary Efficacy Results from a Phase II Study Evaluating Combined BRAF and MEK Inhibition in Relapsed/Refractory Multiple Myeloma (rrMM) Patients with Activating BRAF V600E Mutations: The GMMG-Birma Trial. <i>Blood</i> , 2020, 136, 44-45.	1.4	16

#	ARTICLE	IF	CITATIONS
199	Genetic changes of non-small cell lung cancer under neoadjuvant therapy. <i>Oncotarget</i> , 2016, 7, 29761-29769.	1.8	16
200	Reversion-inducing cysteine-rich protein with Kazal motif (RECK) expression: an independent prognostic marker of survival in colorectal cancer. <i>Human Pathology</i> , 2012, 43, 1314-1321.	2.0	15
201	Basket Trials: Just the End of the First Quarter. <i>Journal of Clinical Oncology</i> , 2015, 33, 2823-2824.	1.6	15
202	Health Care Infrastructure for Financially Sustainable Clinical Genomics. <i>Journal of Molecular Diagnostics</i> , 2016, 18, 697-706.	2.8	15
203	Chloroquine enhances the antimycobacterial activity of isoniazid and pyrazinamide by reversing inflammation-induced macrophage efflux. <i>International Journal of Antimicrobial Agents</i> , 2017, 50, 55-62.	2.5	15
204	Qualitative Comparison Between Carrier-based and Classical Tissue Microarrays. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2017, 25, e74-e79.	1.2	15
205	Integrating proteomics into precision oncology. <i>International Journal of Cancer</i> , 2021, 148, 1438-1451.	5.1	15
206	Assigning evidence to actionability: An introduction to variant interpretation in precision cancer medicine. <i>Genes Chromosomes and Cancer</i> , 2022, 61, 303-313.	2.8	15
207	Comparison of different semi-automated cfDNA extraction methods in combination with UMI-based targeted sequencing. <i>Oncotarget</i> , 2019, 10, 5690-5702.	1.8	15
208	The impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertions. <i>European Journal of Cancer</i> , 2022, 170, 106-118.	2.8	15
209	Radiosensitization by histone deacetylase inhibition in an osteosarcoma mouse model. <i>Strahlentherapie Und Onkologie</i> , 2013, 189, 957-966.	2.0	14
210	DNA Index as a Strong Prognostic Factor in Patients With Adenocarcinoma of the Pancreatic Head. <i>Pancreas</i> , 2013, 42, 807-812.	1.1	14
211	Histone deacetylase inhibition sensitizes osteosarcoma to heavy ion radiotherapy. <i>Radiation Oncology</i> , 2015, 10, 146.	2.7	14
212	Patient-specific molecular alterations are associated with metastatic clear cell renal cell cancer progressing under tyrosine kinase inhibitor therapy. <i>Oncotarget</i> , 2017, 8, 74049-74057.	1.8	14
213	Next generation sequencing of the cellular and liquid fraction of pancreatic cyst fluid supports discrimination of IPMN from pseudocysts and reveals cases with multiple mutated driver clones: First findings from the prospective ZYSTEUS biomarker study. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 3-11.	2.8	14
214	Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary. <i>International Journal of Cancer</i> , 2020, 146, 3053-3064.	5.1	14
215	Decreased RECK and Increased EMMPRIN Expression in Urothelial Carcinoma of the Bladder Are Associated with Tumor Aggressiveness. <i>Pathobiology</i> , 2011, 78, 123-131.	3.8	13
216	Prolyl Hydroxylase Domain 2 Protein Is a Strong Prognostic Marker in Human Gastric Cancer. <i>Pathobiology</i> , 2012, 79, 11-17.	3.8	13

#	ARTICLE	IF	CITATIONS
217	Comprehensive analysis of clinico-pathological data reveals heterogeneous relations between atherosclerosis and cancer. <i>Journal of Clinical Pathology</i> , 2014, 67, 482-490.	2.0	13
218	Prediction of significant prostate cancer in biopsy-naïve men: Validation of a novel risk model combining MRI and clinical parameters and comparison to an ERSPC risk calculator and PI-RADS. <i>PLoS ONE</i> , 2019, 14, e0221350.	2.5	13
219	Morphomolecular analysis of the immune tumor microenvironment in human head and neck cancer. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1443-1454.	4.2	13
220	Serial liquid biopsies for detection of treatment failure and profiling of resistance mechanisms in <i>KLC1</i>“ALK</i>-rearranged lung cancer. <i>Journal of Physical Education and Sports Management</i> , 2019, 5, a004630.	1.2	13
221	Successful BRAF/MEK inhibition in a patient with <i>BRAF</i>^{V600E}-mutated extrapancreatic acinar cell carcinoma. <i>Journal of Physical Education and Sports Management</i> , 2020, 6, a005553.	1.2	13
222	Mass Spectrometry Imaging for Reliable and Fast Classification of Non-Small Cell Lung Cancer Subtypes. <i>Cancers</i> , 2020, 12, 2704.	3.7	13
223	Clinical and molecular practice of European thoracic pathology laboratories during the COVID-19 pandemic. The past and the near future. <i>ESMO Open</i> , 2021, 6, 100024.	4.5	13
224	KRAS / GNAS testing by highly sensitive deep targeted next generation sequencing improves the endoscopic ultrasound-guided workup of suspected mucinous neoplasms of the pancreas. <i>Genes Chromosomes and Cancer</i> , 2021, 60, 489-497.	2.8	13
225	Local ablative treatment with surgery and/or radiotherapy in single-site and oligometastatic carcinoma of unknown primary. <i>European Journal of Cancer</i> , 2021, 157, 179-189.	2.8	13
226	TP53 co-mutations as an independent prognostic factor in 2nd and further line therapy-EGFR mutated non-small cell lung cancer IV patients treated with osimertinib. <i>Translational Lung Cancer Research</i> , 2022, 11, 4-13.	2.8	13
227	The DNA index is a strong predictive marker in intrahepatic cholangiocarcinoma: the results of a five-year prospective study. <i>Surgery Today</i> , 2014, 44, 1336-1342.	1.5	12
228	PARP inhibition in BRCA2-mutated prostate cancer. <i>Annals of Oncology</i> , 2017, 28, 189-191.	1.2	12
229	High prevalence of DNA damage repair gene defects and TP53 alterations in men with treatment-naïve metastatic prostate cancer – Results from a prospective pilot study using a 37 gene panel. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 637.e17-637.e27.	1.6	12
230	Case Report: Abdominal Lymph Node Metastases of Parathyroid Carcinoma: Diagnostic Workup, Molecular Diagnosis, and Clinical Management. <i>Frontiers in Endocrinology</i> , 2021, 12, 643328.	3.5	12
231	CCI-779 (Temsilolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab. <i>Journal of Translational Medicine</i> , 2015, 13, 106.	4.4	11
232	Genomics of Immunotherapy-Associated Hyperprogressors – Letter. <i>Clinical Cancer Research</i> , 2017, 23, 6374-6375.	7.0	11
233	Metastatic adult pancreatoblastoma: Multimodal treatment and molecular characterization of a very rare disease. <i>Pancreatology</i> , 2020, 20, 425-432.	1.1	11
234	Laboratory-Developed Tests in the New European Union 2017/746 Regulation: Opportunities and Risks. <i>Clinical Chemistry</i> , 2021, 68, 40-42.	3.2	11

#	ARTICLE	IF	CITATIONS
235	Semiconductorâ€Based Sequencing of Formalinâ€Fixed, Paraffinâ€Embedded Colorectal Cancer Samples. <i>Oncologist</i> , 2015, 20, e10-1.	3.7	10
236	Histological tumor typing in the age of molecular profiling. <i>Pathology Research and Practice</i> , 2015, 211, 897-900.	2.3	10
237	Several genotypes, one phenotype: PIK3CA/AKT1 mutation-negative hidradenoma papilliferum show genetic lesions in other components of the signalling network. <i>Pathology</i> , 2019, 51, 362-368.	0.6	10
238	Distinct immune evasion in <scp>APOBEC</scp>â€enriched, <scp>HPV</scp>â€negative <scp>HNSCC</scp>. <i>International Journal of Cancer</i> , 2020, 147, 2293-2302.	5.1	10
239	Immunoâ€oncology gene expression profiling of formalinâ€fixed and paraffinâ€embedded clear cell renal cell carcinoma: Performance comparison of the <scp>NanoString nCounter</scp> technology with targeted <scp>RNA</scp> sequencing. <i>Genes Chromosomes and Cancer</i> , 2020, 59, 406-416.	2.8	10
240	Primary neoplasms of the parapharyngeal space: diagnostic and therapeutic pearls and pitfalls. <i>European Archives of Oto-Rhino-Laryngology</i> , 2021, 278, 4933-4941.	1.6	10
241	<scp><i>RREB1â€MKL2</i></scp> fusion in a spindle cell sinonasal sarcoma: biphenotypic sinonasal sarcoma or ectomesenchymal chondromyxoid tumor in an unusual site?. <i>Genes Chromosomes and Cancer</i> , 2021, 60, 565-570.	2.8	10
242	Feasibility and Challenges for Sequential Treatments in ALK-Rearranged Non-Small-Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 670483.	2.8	10
243	<scp>Homologous recombination deficiency</scp> is inversely correlated with <scp>microsatellite instability</scp> and identifies immunologically cold tumors in most cancer types. <i>Journal of Pathology: Clinical Research</i> , 2022, 8, 371-382.	3.0	10
244	Comprehensive serial biobanking in advanced NSCLC: feasibility, challenges and perspectives. <i>Translational Lung Cancer Research</i> , 2020, 9, 1000-1014.	2.8	9
245	Knowledge bases and software support for variant interpretation in precision oncology. <i>Briefings in Bioinformatics</i> , 2021, 22, .	6.5	9
246	Effect of timing, technique and molecular features on brain control with local therapies in oncogene-driven lung cancer. <i>ESMO Open</i> , 2021, 6, 100161.	4.5	9
247	Detection of PD-L1 in the urine of patients with urothelial carcinoma of the bladder. <i>Scientific Reports</i> , 2021, 11, 14244.	3.3	9
248	Next-generation sequencing facilitates detection of the classic E13-A20 EML4-ALK fusion in an ALK-FISH/IHC inconclusive biopsy of a stage IV lung cancer patient: a case report. <i>Diagnostic Pathology</i> , 2016, 11, 133.	2.0	8
249	Synonymous EGFR variant p.Q787Q is neither prognostic nor predictive in patients with lung adenocarcinoma. <i>Genes Chromosomes and Cancer</i> , 2017, 56, 214-220.	2.8	8
250	Proteogenomic systems analysis identifies targeted therapy resistance mechanisms in EGFRâ€mutated lung cancer. <i>International Journal of Cancer</i> , 2019, 144, 545-557.	5.1	8
251	Mass Spectrometry Imaging Differentiates Chromophobe Renal Cell Carcinoma and Renal Oncocytoma with High Accuracy. <i>Journal of Cancer</i> , 2020, 11, 6081-6089.	2.5	8
252	Combination of Crizotinib and Osimertinib in T790M+ EGFR-Mutant Non-Small Cell Lung Cancer with Emerging MET Amplification Post-Osimertinib Progression in a 10-Year Survivor: A Case Report. <i>Case Reports in Oncology</i> , 2021, 14, 477-482.	0.7	8

#	ARTICLE	IF	CITATIONS
253	Targeting rare and non-canonical driver variants in NSCLC – An uncharted clinical field. Lung Cancer, 2021, 154, 131-141.	2.0	8
254	Complete Metabolic Response in FDG-PET-CT Scan before Discontinuation of Immune Checkpoint Inhibitors Correlates with Long Progression-Free Survival. Cancers, 2021, 13, 2616.	3.7	8
255	Comprehensive Dissection of Treatment Patterns and Outcome for Patients With Metastatic Large-Cell Neuroendocrine Lung Carcinoma. Frontiers in Oncology, 2021, 11, 673901.	2.8	8
256	Mutations in TP53 or DNA damage repair genes define poor prognostic subgroups in primary prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 8.e11-8.e18.	1.6	8
257	Molecular dissection of large cell carcinomas of the lung with null immunophenotype. Pathology, 2018, 50, 530-535.	0.6	7
258	Primary pulmonary myxoid sarcoma with an unusual gene fusion between exon 7 of EWSR1 and exon 5 of CREB1. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 476, 787-791.	2.8	7
259	Durvalumab in frail and elderly patients with stage four non-small cell lung cancer: Study protocol of the randomized phase II DURATION trial. Trials, 2020, 21, 352.	1.6	7
260	Comparison of single-scanner single-protocol quantitative ADC measurements to ADC ratios to detect clinically significant prostate cancer. European Journal of Radiology, 2021, 136, 109538.	2.6	7
261	Hidden Treasures: Macrophage Long Non-Coding RNAs in Lung Cancer Progression. Cancers, 2021, 13, 4127.	3.7	7
262	Implementation of a novel efficacy score to compare sealing and cutting devices in a porcine model. Surgical Endoscopy and Other Interventional Techniques, 2018, 32, 1002-1011.	2.4	6
263	Integrated Histogenetic Analysis Reveals BAP1 -Mutated Epithelioid Mesothelioma in a Patient With Cancer of Unknown Primary. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 677-682.	4.9	6
264	Immunohistological expression of oestrogen receptor, progesterone receptor, mammaglobin, human epidermal growth factor receptor 2 and GATA-binding protein 3 in non-small cell lung cancer. Histopathology, 2020, 77, 900-914.	2.9	6
265	Conventional and semi-automatic histopathological analysis of tumor cell content for multigene sequencing of lung adenocarcinoma. Translational Lung Cancer Research, 2021, 10, 1666-1678.	2.8	6
266	SWI/SNF-deficient undifferentiated/rhabdoid carcinoma of the gallbladder carrying a POLE mutation in a 30-year-old woman: a case report. Diagnostic Pathology, 2021, 16, 52.	2.0	6
267	High tumour mutational burden and EGFR/MAPK pathway activation are therapeutic targets in metastatic porocarcinoma. British Journal of Dermatology, 2021, , .	1.5	6
268	Prolonged Survival of a Patient with Advanced-Stage Combined Hepatocellular-Cholangiocarcinoma. Case Reports in Gastroenterology, 2021, 14, 658-667.	0.6	6
269	Rationale and design of the CRAFT (Continuous ReAssessment with Flexible ExTension in Rare) Tj ETQq1 1 0.784314 rgBT /Overlock 10	4.5	6
270	Visceral leishmaniasis in a patient with AIDS: early pathological diagnosis using conventional histology, PCR and electron microscopy is the key for adequate treatment. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 460, 357-360.	2.8	5

#	ARTICLE	IF	CITATIONS
271	Deconvolution of sarcoma methylomes reveals varying degrees of immune cell infiltrates with association to genomic aberrations. <i>Journal of Translational Medicine</i> , 2021, 19, 204.	4.4	5
272	Status quo of ALK testing in lung cancer: results of an EQA scheme based on in-situ hybridization, immunohistochemistry, and RNA/DNA sequencing. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 479, 247-255.	2.8	5
273	Histological and Molecular Plasticity of ALK-positive Non-Small-Cell Lung Cancer under Targeted Therapy - a Case Report. <i>Journal of Physical Education and Sports Management</i> , 2022, , mcs.a006156.	1.2	5
274	Early Development of Ubiquitous Acanthocytosis and Extravascular Hemolysis in Lung Cancer Patients Receiving Alectinib. <i>Cancers</i> , 2022, 14, 2720.	3.7	5
275	Analysis of the proliferative activity in lung adenocarcinomas with specific driver mutations. <i>Pathology Research and Practice</i> , 2018, 214, 408-416.	2.3	4
276	loncopy: an R Shiny app to call copy number alterations in targeted NGS data. <i>BMC Bioinformatics</i> , 2018, 19, 157.	2.6	4
277	Prostatic metastasis from intrahepatic cholangiocarcinoma. <i>Urology Case Reports</i> , 2018, 20, 90-91.	0.3	4
278	Adaptive Immunity and Pathogenesis of Diabetes: Insights Provided by the $\alpha 4\beta 2$ Integrin Deficient NOD Mouse. <i>Cells</i> , 2020, 9, 2597.	4.1	4
279	Ruxolitinib is effective in the treatment of a patient with refractory T α ALL. <i>EJHaem</i> , 2021, 2, 139-142.	1.0	4
280	De Novo Versus Secondary Metastatic EGFR-Mutated Non-Small-Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 640048.	2.8	4
281	Prognostic impact of copy number alterations and tumor mutational burden in carcinoma of unknown primary. <i>Genes Chromosomes and Cancer</i> , 2022, 61, 551-560.	2.8	4
282	Mutations of cancer-related genes in benign tumors: the example of hidradenoma papilliferum. <i>Human Pathology</i> , 2017, 62, 246-247.	2.0	3
283	Oncogene-induced senescence: a potential breakpoint mechanism against malignant transformation in plasma cell disorders. <i>Leukemia and Lymphoma</i> , 2018, 59, 2660-2669.	1.3	3
284	Strength in numbers: predicting response to checkpoint inhibitors from large clinical datasets. <i>Cell</i> , 2021, 184, 571-573.	28.9	3
285	Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: study protocol of the ABP trial. <i>BMC Cancer</i> , 2021, 21, 743.	2.6	3
286	Distinct Mutational Profile of Lynch Syndrome Colorectal Cancers Diagnosed under Regular Colonoscopy Surveillance. <i>Journal of Clinical Medicine</i> , 2021, 10, 2458.	2.4	3
287	Cutaneous epithelioid haemangiomas show somatic mutations in the mitogen-activated protein kinase pathway. <i>British Journal of Dermatology</i> , 2022, 186, 553-563.	1.5	3
288	Impact of Surgeon's Experience in Rigid Versus Elastic MRI/TRUS-Fusion Biopsy to Detect Significant Prostate Cancer Using Targeted and Systematic Cores. <i>Cancers</i> , 2022, 14, 886.	3.7	3

#	ARTICLE	IF	CITATIONS
289	Brief Report: A Blood-Based MicroRNA Complementary Diagnostic Predicts Immunotherapy Efficacy in Advanced-Stage NSCLC With High Programmed Death-Ligand 1 Expression. JTO Clinical and Research Reports, 2022, 3, 100369.	1.1	3
290	KIT mutations in primary mediastinal B-cell lymphoma. Blood Cancer Journal, 2014, 4, e241-e241.	6.2	2
291	Rearranged ERG confers robustness to prostate cancer cells by subverting the function of p53. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 736.e1-736.e10.	1.6	2
292	PARP inhibition in prostate cancer. Genes Chromosomes and Cancer, 2021, 60, 344-351.	2.8	2
293	Validation of a Targeted Next-Generation Sequencing Panel for Tumor Mutation Burden Analysis. Journal of Molecular Diagnostics, 2021, 23, 882-893.	2.8	2
294	Profiling of Oncogenic Signaling in Multiple Myeloma – Association with Biology, Disease Progression and Prognosis. Blood, 2018, 132, 3206-3206.	1.4	1
295	Abstract 449: A standard operating procedure for the curation of gene fusions. , 2021, , .		0
296	Absence Of BRAF and KRAS Hotspot Mutations In Primary Mediastinal and Other Diffuse Large B-Cell Lymphoma. Blood, 2013, 122, 4325-4325.	1.4	0
297	Implementation of a novel efficacy score to compare sealing and cutting devices in a porcine model. , 2017, 77, .		0
298	MiRNAs involved in development of intraepithelial precursor lesions and progression to cholangiocarcinoma. Zeitschrift Fur Gastroenterologie, 2019, 57, .	0.5	0
299	Cholangiocarcinogenesis is a developmental process driven by distinct sequential alterations of the cellular transcriptome. , 2019, 57, .		0
300	RSPO2 gene rearrangement – a new cancer driver in the liver. Zeitschrift Fur Gastroenterologie, 2019, 57, .	0.5	0
301	TP53 status conversion defines an unfavourable patient subset with inferior overall survival in ALK+ lung adenocarcinoma. , 2019, 73, .		0
302	A framework for risk stratification in EGFR+ lung adenocarcinoma treated with tyrosine kinase inhibitors. , 2019, 73, .		0
303	IMPACT OF DEEP TARGETED NEXT GENERATION SEQUENCING ON THE WORK-UP OF PATIENTS WITH PANCREAS CYSTS OR DILATED DUCT - A PROSPECTIVE STUDY WITH EUS-GUIDED FNA. Endoscopy, 2020, 52, .	1.8	0
304	Clinical and molecular profile of de novo vs. secondary EGFR mutated metastatic non-small-cell lung cancer. Pneumologie, 2020, 74, .	0.1	0